Rigel Pharmaceuticals just saw its fair value estimate nudged from US$51.20 to US$51.60, a small move that still reflects some meaningful shifts in the story behind the stock. The model now blends ...

Rigel Pharmaceuticals recently issued full-year 2026 guidance, projecting total revenue of about US$275 million to US$290 ...

Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...

Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Here's why this stock's big run-up in recent months could be just the beginning. A new collaboration deal with a big pharmaceutical company isn't the only reason to keep an eye on this often ...

CEO Raul Rodriguez highlighted "year-over-year net product sales growth of 68%" and total revenue of $53.3 million for Q1 2025. He noted that Rigel achieved $11.4 million in net income for the quarter ...

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it has received guidance from the U.S. Food and Drug Administration (FDA)'s review of ...

CEO Raul Rodriguez highlighted, “For the third quarter, we reported total revenue of $69.5 million, including record net product sales of $64.1 million, a 65% year-over-year increase.” He noted that ...

LOUISVILLE, Ky., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Onco360 ®, the nation’s leading independent specialty pharmacy, has been chosen by Rigel Pharmaceuticals as limited distribution specialty pharmacy ...